+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019

  • ID: 4894229
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 2792 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4SC AG
  • AstraZeneca Plc
  • Celgene Corp
  • Exonate Ltd
  • Immune System Key Ltd
  • Magenta Therapeutics Inc
  • MORE
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 131, 123, 2, 8, 219, 34 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 16, 18, 3, 1, 43 and 27 molecules, respectively.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4SC AG
  • AstraZeneca Plc
  • Celgene Corp
  • Exonate Ltd
  • Immune System Key Ltd
  • Magenta Therapeutics Inc
  • MORE
Introduction
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ABL Bio Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advanced BioDesign, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AI Therapeutics, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aleta Biotherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AlfaSigma SpA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Allogene Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amphivena Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amplia Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ANP Technologies Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AnyGen Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea Therapeutics AB, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AptaBio Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aravive Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arcellx Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Argenx SE, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arvinas Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascentage Pharma Group International, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ATP Biopharm, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AUM Biosciences Pte Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Auransa Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Oncology Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avidin Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVROBIO Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avvinity Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bantam Pharmaceutical LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beam Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beijing Immunochina Medical Science & Technology Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2019

List of Figures
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4SC AG
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AB Science SA
  • AbbVie Inc
  • ABL Bio Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics SA
  • Adlai Nortye Biopharma Co Ltd
  • Advanced BioDesign
  • Advenchen Laboratories LLC
  • Aeglea BioTherapeutics Inc
  • Affichem SA
  • Agios Pharmaceuticals Inc
  • AI Therapeutics
  • Aileron Therapeutics Inc
  • AIMM Therapeutics BV
  • Aleta Biotherapeutics Inc
  • AlfaSigma SpA
  • Allogene Therapeutics Inc
  • Amgen Inc
  • Amphivena Therapeutics Inc
  • Amplia Therapeutics Ltd
  • Angiocrine Bioscience Inc
  • Anhui Anke Biotechnology (Group) Co Ltd
  • ANP Technologies Inc
  • Antisense Therapeutics Ltd
  • AnyGen Co Ltd
  • APIM Therapeutics AS
  • Aprea Therapeutics AB
  • AptaBio Therapeutics Inc
  • Aptevo Therapeutics Inc
  • Aptose Biosciences Inc
  • Aravive Inc
  • Arcellx Inc
  • Argenx SE
  • Arog Pharmaceuticals Inc
  • Arrien Pharmaceuticals LLC
  • Arvinas Inc
  • Ascentage Pharma Group International
  • Aslan Pharmaceuticals Ltd
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Athenex Inc
  • ATP Biopharm
  • AUM Biosciences Pte Ltd
  • Auransa Inc
  • Aurigene Discovery Technologies Ltd
  • AVEO Oncology Inc
  • Avidin Ltd
  • AVROBIO Inc
  • Avvinity Therapeutics Ltd
  • Bantam Pharmaceutical LLC
  • Bayer AG
  • BCI Pharma SA
  • Beam Therapeutics Inc
  • Beijing Immunochina Medical Science & Technology Co Ltd
  • Bellicum Pharmaceuticals Inc
  • BerGenBio ASA
  • Betta Pharmaceuticals Co Ltd
  • Bio-Cancer Treatment International Ltd
  • Bio-Path Holdings Inc
  • Biokine Therapeutics Ltd
  • BioLineRx Ltd
  • BioMed Valley Discoveries Inc
  • Bionetix Inc
  • Bionomics Ltd
  • BioSight Ltd
  • BioTheryX Inc
  • BioXcel Therapeutics Inc
  • BiVictriX Therapeutics Ltd
  • bluebird bio Inc
  • Blueprint Medicines Corp
  • Boehringer Ingelheim International GmbH
  • Boryung ViGenCell Inc
  • Boston Biomedical Inc
  • BoYen Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Canqura Oncology AB
  • Cantargia AB
  • Carrick Therapeutics UK Ltd
  • Catalent Inc
  • Celgene Corp
  • CellCentric Ltd
  • Cellectis SA
  • Cellerant Therapeutics Inc
  • Cellipse SAS
  • Cellular Biomedicine Group Inc
  • Celularity Inc
  • Celyad SA
  • Centrose LLC
  • Changzhou Qianhong Bio-Pharma Co Ltd
  • CharlestonPharma LLC
  • Checkpoint Therapeutics Inc
  • Chimerix Inc
  • Chordia Therapeutics Inc
  • Chugai Pharmaceutical Co Ltd
  • Clear Creek Bio Inc
  • Cleave Therapeutics Inc
  • Constellation Pharmaceuticals Inc
  • ConverGene LLC
  • CRISPR Therapeutics AG
  • CrystalGenomics Inc
  • CSPC Pharmaceutical Group Ltd
  • CuronBiotech Inc
  • Cyclacel Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Dalriada Therapeutics Inc
  • DC Prime BV
  • Deciphera Pharmaceuticals Inc
  • Delta-Fly Pharma Inc
  • Demuris Ltd
  • Denovo Biopharma LLC
  • DiNonA Inc
  • Dong-A ST Co Ltd
  • Eli Lilly and Co
  • Emercell SAS
  • Eminent Biosciences
  • EntreChem SL
  • Epigene Therapeutics Inc
  • Epizyme Inc
  • Escend Pharmaceuticals Inc
  • ExCellThera Inc
  • Exelixis Inc
  • Exonate Ltd
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Flavocure Biotech LLC
  • Forma Therapeutics Inc
  • Formula Pharmaceuticals Inc
  • Fortress Biotech Inc
  • Forty Seven Inc
  • Fujifilm Holdings Corp
  • Gadeta BV
  • Gamida Cell Ltd
  • GC Pharma
  • GEMoaB Monoclonals GmbH
  • Genentech Inc
  • Genosco Inc
  • Genus Oncology LLC
  • Geron Corp
  • GlaxoSmithKline Plc
  • GlycoMimetics Inc
  • Glycostem Therapeutics BV
  • GO Therapeutics Inc
  • Golden Biotechnology Corp
  • GT Biopharma Inc
  • H3 Biomedicine Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Hebei Senlang Biotechnology Inc Ltd
  • HEC Pharm Co Ltd
  • Hefei Cosource Pharmaceutical Inc
  • Helocyte Biosciences Inc
  • HemoGenyx LLC
  • HighPass Bio Inc
  • Hinova Pharmaceuticals Inc
  • Hoverink Biotechnologies Inc
  • HRAIN Biotechnology Co Ltd
  • Hummingbird Bioscience Pte Ltd
  • Hybrigenics SA
  • I-Mab Biopharma Co Ltd
  • iCell Gene Therapeutics LLC
  • IGF Oncology LLC
  • IGM Biosciences Inc
  • Imago BioSciences Inc
  • Immune Onc Therapeutics Inc
  • Immune System Key Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Inatherys
  • Incuron LLC
  • Incysus Therapeutics Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • Inmune Bio Inc
  • Innovation Pharmaceuticals Inc
  • Intellia Therapeutics Inc
  • Interprotein Corp
  • Intra-Immusg Pvt Ltd
  • Io Therapeutics Inc
  • Iovance Biotherapeutics Inc
  • Iterion Therapeutics
  • Jay Pharma Inc
  • Jazz Pharmaceuticals Plc
  • Jeil Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • JSK Therapeutics Inc
  • Jubilant Biosys Ltd
  • Juno Therapeutics Inc
  • Juventas Cell Therapy Ltd
  • JW Pharmaceutical Corp
  • Kainos Medicine Inc
  • Kartos Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Keystone Nano Inc
  • Kiadis Pharma NV
  • KinaRx LLC
  • KisoJi Biotechnology Inc
  • Komipharm International Co Ltd
  • Konruns Pharmaceutical Co Ltd
  • Kura Oncology Inc
  • Kymera Therapeutics LLC
  • Laekna Therapeutics Shanghai Co Ltd
  • Lai Corporation Pty Ltd
  • Lead Discovery Center GmbH
  • Les Laboratoires Servier SAS
  • Leukos Biotech SL
  • Lineage Cell Therapeutics Inc
  • Machavert Pharmaceuticals LLC
  • MacroGenics Inc
  • Magenta Therapeutics Inc
  • Mana Therapeutics Inc
  • Marker Therapeutics Inc
  • Mateon Therapeutics Inc
  • MaxCyte Inc
  • Maxinovel Pharmaceuticals
  • MedAbome Inc
  • MediGene AG
  • Medivir AB
  • MEI Pharma Inc
  • Merck & Co Inc
  • Merck KGaA
  • Merus NV
  • Meryx Inc
  • Millennium Pharmaceuticals Inc
  • Minneamrita Therapeutics LLC
  • Miragen Therapeutics Inc
  • MiRx Pharmaceuticals LLC
  • Molecular Templates Inc
  • Molecules For Health Inc
  • Moleculin Biotech LLC
  • MolMed SpA
  • Mustang Bio Inc
  • MyeloRx LLC
  • Nanjing Legend Biotech Co Ltd
  • Nanjing Sanhome Pharmaceutical Co Ltd
  • Nanovalent Pharmaceuticals Inc
  • NantKwest Inc
  • Nemucore Medical Innovations Inc
  • Newave Pharmaceutical Inc
  • NewLink Genetics Corp
  • NexImmune Inc
  • Nkarta Inc
  • NMS Group SpA
  • Nohla Therapeutics Inc
  • Northlake International LLC
  • Novartis AG
  • OHM Oncology
  • Omeros Corp
  • Oncoceutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll